Market-watcher sees double-digit growth for disposables; CMO will refurbish factory bought from Pfizer;

> High Tech Business Decisions says it expects the market for single-use systems to grow at double-digit rates, with similar growth rates for disposables supporting both upstream and downstream bioprocesses. Article (sub. req.)

> European contract manufacturer Fareva plans to continue operating the factory in Henrico, VA, it's buying from Pfizer ($PFE) and invest $42 million. Story

> Twin-screw extrusion, a process common in the plastics industry, is being studied at Bradford University for use in making co-crystals, which offer an alternative means of creating targeted soluble drug compounds. Story

> GLP- and GMP-compliant contract lab Advantar, which provides analytical and formulation development services, has entered a non-exclusive strategic alliance with DavosPharma, provider of chemistry and pharma development management solutions. Item

> Big 3 Distributor AmerisourceBergen ($ABC) has acquired Premier Source, a reimbursement consultancy to medical device, pharma, molecular diagnostic and biotechnology manufacturers. AmericasourceBergen release

> Generic drugmakers must ensure their products follow the same scoring practices as references drugs. Draft guidance

> Pfizer says it has signed a 10-year lease with the Massachusetts Institute of Technology (MIT) for more than 180,000 square feet in a new building under development in Cambridge, MA, for cardiovascular R&D. Story

Suggested Articles

Teva will produce its new migraine drug at a plant in Israel and more news of note.

The shortage of childhood cancer drug vincristine was front and center during the Senate hearing for Stephen Hahn, nominee for FDA commissioner.

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.